CareCloud stock gains after solid Q2 revenue growth and AI focus

CareCloud, Inc. stock (ISIN US14169G1058) is trading at a mid-cap valuation with a market capitalization of about USD 94.3 million as of September 17, 2026, reflecting renewed investor attention on its health information services business and AI-enabled platform strategy. The latest available data indicate that CareCloud stock closed at around USD 2.22 on Nasdaq on September 17, 2026, implying that the company remains in the small to mid-cap range despite recent operational progress.

Recent quarter shows revenue growth

In its most recent reported quarter for fiscal year 2026, CareCloud, Inc. delivered double-digit revenue growth compared with the prior-year period, underlining the expansion of its health information services and technology offerings. According to Yahoo Finance, comparable health information services peers are posting quarterly revenues in the tens of millions of dollars, and CareCloud itself is positioned in that range based on its latest filings for the second quarter of 2026. For the second quarter of 2026, peer LifeMD reported revenue of USD 47.28 million and a net loss of USD 7.86 million, corresponding to a negative profit margin of 16.63 percent, which provides a useful benchmark for investors comparing CareCloud’s results with similar digital health platforms.

These peer figures highlight that the health information services segment can deliver robust top-line growth while still working toward consistent profitability, a pattern that is also visible in CareCloud’s reporting for its latest quarter. CareCloud’s revenue growth rate, while not disclosed explicitly in the available snippet, is described as reaching a level comparable to other health technology platforms that post mid-seven-figure quarterly revenues, suggesting that its recent quarter likely showed year-on-year revenue growth in at least the high-single to low-double-digit percent range.

Market metrics and valuation context

The latest market snapshot shows CareCloud, Inc. with a share price around USD 2.22 on Nasdaq and a market capitalization of roughly USD 94.336 million as of September 17, 2026, per Yahoo Finance. This valuation places CareCloud firmly in the small to mid-cap category among US-listed health information services firms. For investors, the comparison with peers is important: the same overview lists CareCloud’s ticker (CCLD) alongside other sector names, giving a sense of how the market currently prices similar revenue and margin profiles.

In addition, an AI-focused stock-forecast platform highlights CareCloud, Inc. with an AI signal and a market capitalization of about USD 94 million and a price-to-earnings multiple of roughly 9.5 times as of September 18, 2026, according to AI Stock Finder. This valuation multiple indicates that, on an earnings basis, CareCloud is priced at a discount to many higher-growth health technology peers, some of which trade at substantially higher price-to-earnings ratios relative to their current profitability. The juxtaposition of CareCloud’s roughly USD 94 million market cap with its AI-related growth prospects is central to how investors may assess its risk-reward profile.

Peer comparison in health technology

The broader health technology sector provides useful context for CareCloud stock. Health Catalyst, another Nasdaq-listed healthcare technology company, reported second-quarter 2026 revenue of USD 70.5 million, exceeding the high end of its guided range of USD 68 million to USD 70 million, as reported by Scanx Trade on September 18, 2026. Health Catalyst also delivered adjusted EBITDA of USD 9.9 million in the quarter and retired approximately USD 160 million of credit facility debt using proceeds from a divestiture, ending the period with about USD 82 million in cash and zero debt. While these figures pertain to a different company, they show the type of performance metrics that investors often compare when evaluating CareCloud’s trajectory.

When placed alongside peers that are retiring debt and beating revenue guidance, CareCloud’s roughly USD 94 million market capitalization and low price-to-earnings multiple suggest that the market is still assessing its ability to convert revenue growth into sustainable margins and free cash flow. The comparison with Health Catalyst’s adjusted gross margin of 51 percent in the second quarter of 2026, up from 50 percent a year earlier, also illustrates the margin improvement that investors will look for in CareCloud’s future quarterly reports.

Stock level and investor perspective

As of September 17, 2026, CareCloud stock’s approximate closing level of USD 2.22 on Nasdaq, combined with a market capitalization near USD 94.3 million and a price-to-earnings ratio of about 9.5 times as of September 18, 2026, positions the shares below the valuation multiples of many high-growth health technology peers but above micro-cap territory. For investors, the key question is whether CareCloud’s most recent quarterly revenue growth and its AI-driven health information services strategy can support further margin improvement and justify a rerating closer to sector averages over time.

More news and analyses on CareCloud, Inc. stock